BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21213508)

  • 1. Latest innovation in the treatment of osteoporosis: SERMs and the role of parathyroid hormone.
    Thiebaud D
    J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S124-5. PubMed ID: 21213508
    [No Abstract]   [Full Text] [Related]  

  • 2. [Delaying degeneration or promoting regeneration. 2 successful strategies in osteoporosis].
    MMW Fortschr Med; 2004 Mar; 146(10):46. PubMed ID: 15347088
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].
    Takada J; Iba K; Yamashita T; Yoshizaki T
    Clin Calcium; 2010 Mar; 20(3):355-63. PubMed ID: 20190365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoporosis: latest innovation in therapy.
    Taechakraichana N; Witoonpanich P
    J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S126-31. PubMed ID: 21213509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Raloxifene hydrochloride].
    Itabashi A
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():528-35. PubMed ID: 15035185
    [No Abstract]   [Full Text] [Related]  

  • 6. Another selective estrogen-receptor modulator for osteoporosis.
    Becker C
    N Engl J Med; 2010 Feb; 362(8):752-4. PubMed ID: 20181977
    [No Abstract]   [Full Text] [Related]  

  • 7. [Evidence of raloxifene on postmenopausal osteoporosis].
    Okano H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
    [No Abstract]   [Full Text] [Related]  

  • 8. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half].
    MMW Fortschr Med; 2003 May; 145(22):57. PubMed ID: 12866287
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2010 Mar; 20(3):315-21. PubMed ID: 20190360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density.
    Riggs BL; Melton LJ
    J Bone Miner Res; 2002 Jan; 17(1):11-4. PubMed ID: 11771656
    [No Abstract]   [Full Text] [Related]  

  • 12. [Drugs in development for the treatment of osteoporosis:Raloxifene].
    Taga M
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():572-80. PubMed ID: 11979956
    [No Abstract]   [Full Text] [Related]  

  • 13. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
    Ohta H
    Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [MORE study(raloxifene)].
    Itabashi A
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():442-9. PubMed ID: 15035168
    [No Abstract]   [Full Text] [Related]  

  • 15. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
    MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
    [No Abstract]   [Full Text] [Related]  

  • 16. [Relationship between changes in biochemical markers of bone turnover and prediction value of fracture risk].
    Cyaki O
    Clin Calcium; 2004 Oct; 14(10):39-46. PubMed ID: 15577130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raloxifene therapy in the reduction of fractures.
    Cefalu CA
    Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
    [No Abstract]   [Full Text] [Related]  

  • 18. [SERM and quality of bone].
    Sohen S
    Clin Calcium; 2004 Oct; 14(10):96-9. PubMed ID: 15577138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
    MMW Fortschr Med; 2004 May; 146(21):63. PubMed ID: 15373093
    [No Abstract]   [Full Text] [Related]  

  • 20. Lasofoxifene in postmenopausal women with osteoporosis.
    Cummings SR; Ensrud K; Delmas PD; LaCroix AZ; Vukicevic S; Reid DM; Goldstein S; Sriram U; Lee A; Thompson J; Armstrong RA; Thompson DD; Powles T; Zanchetta J; Kendler D; Neven P; Eastell R;
    N Engl J Med; 2010 Feb; 362(8):686-96. PubMed ID: 20181970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.